In a filing, Akero Therapeutics Inc revealed its Chief Development Officer Yale Catriona unloaded Company’s shares for reported $0.53 million on Jul 16 ’25. In the deal valued at $52.95 per share,10,000 shares were sold. As a result of this transaction, Yale Catriona now holds 91,488 shares worth roughly $4.53 million.
Then, Cheng Andrew sold 30,000 shares, generating $1,534,895 in total proceeds. Upon selling the shares at $51.16, the President and CEO now owns 520,757 shares.
Before that, Rolph Timothy sold 12,500 shares. Akero Therapeutics Inc shares valued at $638,661 were divested by the Chief Scientific Officer at a price of $51.09 per share. As a result of the transaction, Rolph Timothy now holds 167,124 shares, worth roughly $8.28 million.
TD Cowen initiated its Akero Therapeutics Inc [AKRO] rating to a Buy in a research note published on August 04, 2025; the price target was $76. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in late January from “a Neutral” to “a Buy”. H.C. Wainwright also remained covering AKRO and reiterated its “Buy” recommendation on January 27, 2025. Citigroup started covering the stock on November 18, 2024. It rated AKRO as “a Buy”.
Price Performance Review of AKRO
On Tuesday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 1.93% to $49.56. Over the last five days, the stock has gained 4.36%. Akero Therapeutics Inc shares have risen nearly 88.08% since the year began. Nevertheless, the stocks have risen 78.15% over the past one year.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-07-15, growing by 0.41 million shares to a total of 8.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 7.75 million shares. There was a rise of 5.06%, which implies that there is a positive sentiment for the stock.